Introduction and hypothesis This study was designed to evaluate the effects of CP55,940 on normal bladder function in vivo and examine whether it suppresses urinary frequency induced by nociceptive stimuli in the bladder. Cannabinoid receptor (CBR) activity may be involved in the regulation of bladder function. However, the role of CBR subtypes in micturition has yet to be established. CP55,940 is a synthetic analogue of tetrahydrocannabidiol, which is a psychoactive ingredient of the Cannabis plant. Methods Cystometry under urethane anaesthesia was performed to evaluate the effect of intravesical delivery of CP55,940 with or without administration of CB1 antagonist AM251 or CB2 antagonist AM630 on bladder function in female rats. The effects of CP55,940 were also examined in rats with urinary irritation induced by intravesical infusion of acetic acid. Results Infusion of CP55,940 significantly (p < 0.05) increased micturition interval (MI) and bladder capacity (BC) by 52 % and decreased maximal voiding pressure (MP) by 25 %. Pretreatment with AM251 or AM630 before CP55,940 administration prevented CP55,940-induced increases in MI, BC and reduced MP. Acetic acid induced urinary frequency as evidenced by a reduction in MI and was suppressed by CP55,940. Conclusions CP55,940 decreases bladder activity and urinary frequency induced by nociceptive stimuli, probably by suppression of bladder afferent activity. Effects of CP55,940 were abolished by both CBR antagonists. This data implicates a role for the endocannabinoid system in bladder mechanoafferent function in rats. In addition, our results show that CP55,940 reverses urinary frequency exemplified in an overactive bladder model, suggesting it could be an effective treatment for patients with lower urinary tract symptoms.
Introduction
The modulation of urge urinary incontinence (UUI) by cannabis in patients with multiple sclerosis (MS) presenting with neurogenic detrusor overactivity (DO) has sparked interest in the functional involvement of the endocannabinoid system (ECS) in the lower urinary tract [1] . The ECS consists of the cannabinoid receptors, their endogenous ligands and enzymes that regulate the biosynthesis and degradation of the endocannabinoids [2] . The presence of the ECS in the urinary bladder has led to speculation that endocannabinoid signalling is involved in signal transduction pathways regulating bladder relaxation and may be involved in pathophysiological processes of the bladder [1] . On the basis of this evidence, it was postulated that activation of cannabinoid receptors (CB1 and CB2) might promote relaxation of the urinary bladder during the filling phase. Dysregulation of the ECS in human bladder may be responsible for the pathogenesis of overactive bladder (OAB) syndrome and DO. We previously localised the components of the ECS in rat and human bladders, showing expression of cannabinoid receptors and the modulating enzymes. Our functional in vitro studies showed that CB1 receptors have both pre-and postsynaptic inhibitory effects on rat bladder contraction, whereas CB2 acts only postsynaptically [3] .
Although the processes involved in the pathogenesis of OAB are quite well understood, molecular and signaltransduction mechanisms involved have not been fully evaluated. The ECS has been suggested as one of these mechanisms [4] . Cystometric studies have shown an increase in micturition threshold in rats receiving systemic cannabinoids in an OAB model induced by acetic acid, cyclophosphamide [5] or turpentine oil [6] . These effects were stronger when the cannabinoids were administered through a close-arterial route rather than systemically through the tail vein, supporting the hypothesis of a local regulatory role of the cannabinoid system in the micturition reflex [6] . Intravesical infusion of acetic acid has been shown to alter the micturition reflex in rats [7] by increasing the frequency of contractions and decreasing bladder capacity (BC), with micturition pressure being either unaffected or increased [8] . We therefore used acetic acid to induce OAB in a rat model [6, 9, 10] , assessing the effects of intravesical delivery of 3-(2-hyd r o x y -4 -( 1 , 1 -d i m e t h y l h e p t y l ) p h e n y l ) -4 -( 3 -hydroxypropyl)cyclo-hexanol (CP55,940) in a pathophysiological state in order to determine its potential use as a therapeutic agent. CP55,940 displays similar affinity for both central and peripheral cannabinoid receptors.
The aim of this study was to characterise the receptor subtype (CB1 or CB2) responsible for mediating normal rat bladder function following intravesical administration of CP55, 940 and investigate its effects on a pathophysiological OAB in rat.
Methods Animals
Twenty-seven adult female Sprague-Dawley rats (n = 5−6 per group weighing 250-300 g, Charles River, UK) were group housed in an environmentally controlled room with a 12-h light/dark cycle and unlimited access to food and water. All experiments were carried out in accordance with the UK Home Office regulations and the Animals (Scientific Procedures) Act 1986. The study had Home Office Licence approval (Project Licence 40/3647 Protocol 19B-3).
General preparation
Anaesthesia was induced and maintained with isoflurane (induction dose 4 %; maintenance dose 1.5-3 %) until intravenous (i.v.) access was obtained. This took an average of 5-10 min. Once the femoral vein was cannulated with an i.v. infusion set containing an injection port and safety device, urethane (1.2 g/kg i.v.) was slowly administered until a suitable depth of anaesthesia (assessed by an absence of hind limb withdrawal in response to paw pinch and absence of corneal reflex) was achieved. Supplementary doses of urethane (0.1 g/kg i.v.) were administered as required. Rats were under urethrane anaesthesia for the duration of the protocol, which on average lasted for 2-2.5 h. Body temperature was maintained at 37°C by placing the animal on a homeothermic blanket system (Harvard, USA) and monitoring changes in temperature using a rectal temperature probe.
Cystometry
The ureters were exposed by retroperitoneal incisions and the distal ends tied and cut to ensure no backflow and hence no leakage of saline from the bladder. The abdomen was opened through a midline incision, and a single cuffed polyethylene catheter (PE-90 1.02 mm, Portex, Kent, UK) was inserted through a small incision into the bladder dome. The catheter was secured with a suture around the top of the bladder dome; this was followed by closure of the abdominal incision. The catheter was connected via a three-way stopcock to a pressure transducer (DTX-plus, Digitimer, Singapore) to record bladder pressure and a syringe pump (Pump33, Harvard Apparatus) for continuous infusion (0.15 ml/min) to evoke the micturition reflex. During cystometry, data was captured using the data acquisition software (LabChart v7.3, AD Instruments, UK). Cystometric parameters, such as micturition interval (MI), baseline pressure (BP), maximum voiding pressure (MP) and BC (calculated as MI × rate of infusion), were measured.
Experimental protocol
A stabilisation period of 30-45 min, with continuous intravesical infusion of 0.9 % w/v sterile saline (0.15 ml/ min) into the bladder was undertaken after completion of surgery. Following the acquisition of stable contractile responses, saline was infused for a further 1 h to evaluate normal bladder activity (control period). This step was repeated for each rat in every experimental group, ensuring there was a control bladder activity trace for each rat.
Experiment 1
The first part of the study was to assess the effect of the vehicle [0.2 % dimethylsulfoxide (DMSO)] on cystometric parameters; six rats were used for this experiment. Each rat underwent a stabilisation period with infused saline, as described above, and served as its own control, with intravesical infusion of saline for 1 h followed by intravesical infusion of the vehicle for 1 h. After completion of the experiments, rats were administered 5 % isoflurane as a schedule-1 method, with euthanasia confirmed by dislocation of the neck.
Experiment 2
In order to explore the effects of nonselective CB agonist CP55,940 on cystometric parameters, five rats were administered CP55,940 (0.005 mg/kg) intravesical ly for 1 h after the saline stabilisation and control period described above. At completion, rats were culled using the Schedule-1 method.
Experiment 3
In experiments examining effects of CB1 receptor antagonist AM251, saline was administered intravesically for 1 h to five rats as a control, previously described above. AM251 (1 mg/kg), was then administered intravenously while the saline intravesical infusion was running. Five minutes after the i.v. antagonist was given, CP55,940 was administered by intravesical infusion for 1 h. At the end of the experiment, the five rats underwent Schedule 1.
Experiment 4
This experiment investigated the effects of CB2 receptor antagonist AM630 in five rats. The experimental procedure described in step 3 was followed using AM630 (3 mg/kg).
Experiment 5
In the studies examining the effect of CP55,940 on irritated bladders (acetic-acid-treated group), six rats were used and underwent a saline stabilization and control period described above. To induce bladder hyperactivity, 0.25 % acetic acid [9, 10] was infused intravesically for 30 min to induce bladder irritation, as previously described by Hiragata et al. [5] . In the same group of rats, intravesical infusion of CP55,940 (0.005 mg/kg) was commenced for 1 h to evaluate its effect on acetic-acid-induced bladder irritation. Rats underwent Schedule 1 after the experiments.
Drugs and solutions
CP55,940 was purchased from Tocris, UK, and was dissolved in DMSO. The dose of 0.005 mg/kg of CP55,940 was based on evidence from a previous study by Gratzke et al. [11] , who demonstrated a significant increase in MI following intravesical infusion of the drug. AM251, the selective CB1 receptor antagonist, and AM630, the selective CB2 antagonist (Tocris) was dissolved in DMSO. The dose of 1 mg/kg used for AM251 was selected as an acceptable dose based on current knowledge that AM251 loses CB1 receptor selectivity at higher concentrations through actions on peroxisome proliferator-activated receptors (PPARs), G-protein-coupled receptors (GPR) 18 and 55. AM630 dose (3 mg/kg) and administration timescale (5 min) were chosen based on previous studies [5, 12] .
Statistical analysis
For data comparison, cystometric parameters were measured for 1 h from drug application. In a 1-h trace, an average of 42 micturition cycles was analysed. A software macro was designed to analyse all micturition cycles in the 1 h control and 1-h experimental traces. All data are expressed as mean ± standard error of the mean (SEM). Student's t test was used to compare cystometric parameters between control with saline and after application of CP55,940 in the same group and was also used to compare CP55,940 and acetic-acid-exposed rats. Kruskal-Wallis with Dunn's multiple comparisons test was used to compare cystometric parameters between CP55,940 and CB receptor antagonists: p < 0.05 was considered significant. GraphPad Prism v6.0 was used for statistical analysis and graph generation.
Results

Rats with normal bladder activity
Representative cystometric traces taken from SpragueDawley rats are presented in Fig. 1(a-d) , showing the effects of vehicle, CP55,940, CB antagonists and acetic acid and saline control. Table 1 ) compared with the saline-treated control. Although there was a 25 ± 2.9 % decrease in MP recorded after iCP55,940 ntravesical administration (p < 0.05, Table 1 ), there was no reproducible change in BP compared with saline intravesical infusion. Addition of DMSO (vehicle) had no effect on any of the cystometric parameters when compared with the saline-treated control (Table 1) .
Pretreatment i.v. with AM251 or AM630 5 min prior to intravesical infusion of CP55,940 inhibited the previously observed increases in MI and BC, as well as the decreases in MP (Fig. 3, Table 1 ). Representative cystometry traces showing the effects of the addition of either AM251 or AM630 prior to infusion of CP55,940 are displayed in Fig. 1b, c, respectively. This postulates a functional role of CB1 and CB2 receptors mediating bladder function.
Acetic-acid-induced hyperactivity
Changes in cystometric parameters were compared with the saline control to ensure that acetic acid had, indeed, induced bladder hyperactivity. The effects of CP55,940 on cystometric parameters were compared with changes induced by acetic acid. Intravesical infusion of acetic acid induced bladder irritation (Fig. 1d) , as shown by a significant 41 ± 6.3 % reduction in MI (p < 0.01) compared with values obtained from the saline control. Acetic acid did not cause any significant changes in MP, BP or BC when compared with saline control. Addition of CP55,940 intravesically in the same rats increased MI by 78 ± 16.7 % (p < 0.05) and reduced MP by 22 ± 5.8 % (p < 0.05, Table 2 ). 
Discussion
The results of this study demonstrate that intravesical infusion of CP55,940 suppressed bladder activity and urinary frequency induced by bladder irritation. The inhibitory effects of CP55,940 appeared to be mediated by both CB1 and CB2 receptor subtypes. Since, MI and BC cystometric parameters can be considered indicators for afferent function of the micturition reflex, and since MP and BP are indicators of motor activity [11] , then the main function of CP55,940 seemed to be modulation of both afferent and motor activity, as it not only induced an increase in MI and BC but also affected MP. In a similar study using intravesical bolus dosing of CP55, 940, an increase in MI and BC was reported, with no changes in MP [11] . Furthermore, the authors of that study did not report the CB receptor subtype involved in mediating these responses [11] . One reason for the difference between the results presented in our study and those reported previously could be differences in methodologies and/or anaesthetic agents used. In our study, isoflurane and urethane i.v. was used to anaesthetise rats, whereas Gratzke et al. [11] used intraperitoneal administration of ketamine and xylazine, and cystometry was performed on conscious rats. It has been reported that ketamine inhibits the micturition reflex [13, 14] : Castroman and Ness reported that ketamine inhibits reflexive bladder responses to the acute stimulus of distension in a dosedependent manner [13] . In addition to the effects of CP55,940 on afferent activity, its effect on motor activity is in accordance with our previously published in vitro studies in which activation of both CB receptors reduced contractions of the detrusor muscle [3] . Taken together, it may be speculated that CP55,940 activates CB receptors directly on the muscle, inhibiting contractility.
The observed effects of CP55,940 on bladder function demonstrated in this study are in agreement with the effects of cannabinoid agonists reported in human clinical trials. In a large randomised controlled trial, patients with neurogenic DO who were randomised to the THC and cannabidiol (CBD) treatment groups reported a significant reduction in UUI episodes compared with placebo [1] . Similarly, in another study, patients with neurogenic DO given a cannabis extract containing THC and CBD demonstrated a reduction in urinary urgency, number of incontinence episodes, frequency and nocturia. In addition, there was an increase in maximum cystometric capacity in these patients [15] , which is in accordance with the cystometric observations described in this study, where CP55,940 increased MI and BC. With the knowledge that cannabinoid agonists are negatively coupled to calcium channels and that they inhibit adenylate cyclase, the mixed picture of cystometric effects described in this study and those reported in the literature is understandable. The increased MI and decreased MP of contractions could be due to inhibition of adenylate cyclase, which may be involved in relaxation of detrusor smooth muscle during urine collection. The alteration of calcium fluxes may decrease neurotransmitter release required for detrusor contractions, and that decrease may manifest as an increase in the volume requirement (demonstrated as an increase in BC). More experiments will clarify these preliminary results.
It appears from our study that the activation of both CB1 and CB2 receptors have inhibitory effects on the bladder, as demonstrated by both CB antagonists blocking the actions of CP55,940. This is supported by a study that suggested a CB2-mediated effect in the rat urinary bladder [15] , where cannabinor-a selective high-affinity CB2 receptor full agonist-was used and resulted in a 44 % increase in MI. In another study that used the nonselective CB receptor agonist WIN55212, an increase in the threshold for micturition was reported in anaesthetised rats, and this effect was counteracted by the CB1 receptor antagonist SR141716A, suggesting a CB1-mediated effect [6] . Similarly, another study using a synthetic analogue of THC (IP-751, also known as Ajulemic acid) at 10 mg/kg reported an increase in MI by 63 % and threshold pressure by 53 %. These effects were blocked by the CB1 antagonist AM251 but not the CB2 antagonist AM630 [5] . In our study, both AM251 and AM630 inhibited the effects of CP55,940, suggesting a role for both CB receptors in urinary bladder function. A reason for this discrepancy between our study and that of Hiragata et al. [5] could be that, in our study, CP55,940 was administered intravesically while in their study, IP-751 was administered systemically. The intravesical route allows instillation of the cannabinoid drug directly to the bladder, thus bypassing any systemic effects. Therefore, the effects of IP-751 on the central nervous system (CNS) cannot be excluded. Another possibility for these differences could be related to the receptor subtype activated when using different agonists, suggesting differences in receptor activation between the urothelium and detrusor muscle. It has been reported that CB1 and CB2 receptor expression is different in the urothelium and detrusor [16] , and so different agonists may differentially activate the endocannabinoid receptor response in each of these specific tissues, resulting in different downstream events. In addition, there may be an element of CB receptor turnover that depends on the type of agonist used, which could explain this discrepancy. This can be assumed, since full reversal of CP55,940 effects seen on some cystometric parameters occurred with both CB1 and CB2 antagonists.
The mechanism by which cannabinoid receptors modulate the micturition reflex is their presence in afferent nerve fibre endings located in the suburothelial layer, which is supported by in vitro studies using CB1 or CB2 receptor agonists; studies using CB1 receptor agonists show they reduce neuronal activity [17] and attenuate bladder contractility as a result of electrical-field stimulation in isolated mouse bladder strips [18] . In rats, anandamide, WIN 55212-2 (a synthetic CB nonselective agonist) and IP-751 suppressed normal bladder activity and urinary frequency induced by bladder irritation, suggesting that the inhibitory effects are in part mediated by CB1 receptors [5, 6, 19] . In conscious rats, cannabinor, a selective CB2 receptor agonist, increased MI and volume by 52 % (p < 0.05) and 96 % (p < 0.01), respectively, and increased the threshold and flow pressures by 73 % (p < 0.01) and 49 % (p < 0.001), respectively [15] . To support the findings described and the results presented in this study, adenosine triphosphate (ATP)-evoked calcitonin gene-related peptide release (CGRP; a neurotransmitter released by sensory nerve endings) was reported to be inhibited by the activation of both CB1 and CB2 receptors after an alteration in the afferent cystometric parameters from the infusion of a CB receptor agonist [20] . However, it is possible that some of the effect could be centrally mediated, and whether these actions are related to CB receptors in the CNS, at peripheral sites in the lower urinary tract or both, needs to be clarified. Furthermore, it is not known which of the two CB receptor subtypes is primarily responsible for the regulation of micturition in different species.
Cannabinoid receptor expression appears to be altered in pathological conditions, as has been shown in a clinical study in which the density of CB1 receptor immunoreactive nerve fibres were increased in the suburothelium of patients with painful bladder syndrome and detrusor overactivity [4] . In addition, CB1 messenger RNA (mRNA) transcripts were increased in patients with chronic bladder pain syndromes [21] , and CB2 transcripts and protein expression was increased in rats with bladder inflammation induced by acrolein [22] . In vivo studies have shown that cannabinoid agonists increased MI by cannabinoid agonists in rat bladders with induced bladder hyperactivity [5, 6, 19, 23] .
The results in our study and those in the literature support a regulatory role for CB1 and CB2 receptor subtypes in both normal bladder function and bladder dysfunction. Furthermore, it is not known which of the two CB receptor isoforms is of primary importance in the regulation of micturition. In this study, both CB1 and CB2 antagonists inhibited the effects of CP55,940 equally. As AM251 and AM630 are known to cross the blood-brain barrier [24, 25] , it can be speculated that CB1-and CB2-receptor-related changes in micturition may result from CNS or peripheral nerve action (or both). It should be kept in mind that genes can compensate for each other, especially as CB1 and CB2 share intracellular pathways (G i/o protein). Therefore, discrepancies in reports of CB receptor subtype involvement in regulation of micturition may very well suggest their multiple functions in different regulatory units of lower urinary tract control attained via systemic or local administration of drugs.
Conclusions
CP55,940 decreased rat bladder activity and urinary frequency induced by bladder nociceptive stimuli, probably by suppression of bladder afferent activity. These effects are modulated by activation of both CB1 and CB2 receptors, suggesting a role for the ECS in bladder mechanoafferent functions in rats. In addition, results of this study showed that intravesical administration of CP55,940 reversed urinary frequency exemplified in an OAB model, suggesting it could potentially be an effective treatment for patients with lower urinary tract symptoms.
